Gilead’s Kite subsidiary has reported new data from the main trial for its CAR-T Yescarta, hoping to encourage greater use of the slow-growing therapy. Updated results from the ZUM
Gilead and other pharma companies stand accused of engaging in a scheme to block cheaper competitors to life-saving HIV drugs from entering the market.
NHS England has announced a deal with AbbVie, Gilead, and Merck, Sharpe and Dohme (MSD) that aims to eliminate hepatitis C from the country - although it has had to drop a 2025 target
Gilead's attempts to find a treatment for nonalcoholic steatohepatitis (NASH) have been dealt another blow after another trial failure for one of its prime candidates to treat the disease.<
Less than a year after coming out of stealth mode with a $65 million first-round last year, artificial intelligence specialist Insitro has already signed its first biopharma partner.